TITLE

Low-Dose ATG Protects against Acute Rejection

PUB. DATE
November 1998
SOURCE
Kidney;Nov/Dec98, Vol. 7 Issue 6, p267
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the study 'Low-Dose ATG Protects against Acute Rejection,' by D. Thibaudin et al published in 1998.
ACCESSION #
5834873

Tags: GRAFT rejection -- Prevention;  GLOBULINS

 

Related Articles

  • Thymoglobulin (ATG-r) Induction in Immunological High Risk Kidney Transplantation. Sopon Jirasiritham; Surasak Kantachuvejsiri; Vasant Sumethkul; Viroon Mavichak; North Techawathanawanna; Rungrote Khunprakant; Siriwan Jirasiritham; Suchin Worawichawong // Thai Journal of Surgery;Oct-Dec2012, Vol. 33 Issue 4, p139 

    Objective: To study the efficacy of the thymoglobulin (ATG-r) as an induction therapy for prevention of rejection in high risk kidney transplantation Materials and Methods: All high risk kidney transplantation patients during 2008-2010 who received thymoglobulin (ATG-r) as induction therapy were...

  • Haploidentical transplantation in patients with acquired aplastic anemia. Ciceri, F; Lupo-Stanghellini, M T; Korthof, E T // Bone Marrow Transplantation;Feb2013, Vol. 48 Issue 2, p183 

    Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive therapy with antithymocyte globulin and lacking an HLA-matched related or unrelated donor. The platforms of both ex...

  • FDA approves second liver transplant drug.  // FDA Consumer;Jul/Aug94, Vol. 28 Issue 6, p2 

    Reports that a new drug for preventing organ rejection in liver transplant patients received approval from the Food and Drug Administration (FDA) on April 8, 1994. Information on Prograf (tacrolimus); Immunosuppressant drugs; Adverse effects.

  • Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients. Ault, Bettina H.; Honaker, Marsha R.; Osama Gaber, A.; Jones, Deborah P.; Duhart, Benjamin T.; Powell, Sandra L.; Hays, Dena W.; Wyatt, Robert J. // Pediatric Nephrology;Oct2002, Vol. 17 Issue 10, p815 

    No data are currently available that describe the clinical outcomes associated with Thymoglobulin (rabbit polyclonal anti-thymocyte globulin) induction in pediatric renal transplant recipients. We report the outcomes of 17 pediatric renal transplant recipients (mean age 10.1�5.2 years)...

  • Less Graft Rejection with Tacrolimus vs. Cyclosporine.  // Kidney;Mar/Apr98, Vol. 7 Issue 2, p80 

    Discusses the abstract of the article 'Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection,' by A.D. Mayer, J. Dmitrewski et al, published in the 1997 issue of the 'Transplantation' journal.

  • Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Ehl, Stephan; Aichele, Peter; Ramseier, Hansruedi; Barchet, Winfried; Hombach, Joachim; Pircher, Hanspeter; Hengartner, Hans; Zinkernagel, Rolf M. // Nature Medicine;Sep98, Vol. 4 Issue 9, p1015 

    We studied antigen-specific T-cell tolerization therapy using skin transplantation across a defined minor histocompatibility antigen difference. Specific tolerization protocols using short-lived peptide or long-lived spleen cells presenting the peptide as antigen prevented graft rejection...

  • Heme oxygenase: Protective gene or Trojan horse. Platt, Jeffrey L.; Nath, Karl A. // Nature Medicine;Dec98, Vol. 4 Issue 12, p1364 

    The induction of heme oxygenase-1 in mouse cardiac allografts that do not show accelerated arteriosclerosis suggests that this enzyme may protect against the chronic rejection of transplants (pages 1392?1396).

  • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Kirk, Allan D.; Burkly, Linda C.; Batty, D. Scott; Baumgartner, Roxanne E.; Berning, Justin D.; Buchanan, Kelvin; Fechner, John H.; Germond, Rhonda L.; Kampen, Robert L.; Patterson, Noelle B.; Swanson, S. John; Tadaki, Douglas K.; TenHoor, Christopher N.; White, Leonard; Knechtle, Stuart J.; Harlan, David M. // Nature Medicine;Jun99, Vol. 5 Issue 6, p686 

    CD154 is the ligand for the receptor CD40. This ligand-receptor pair mediates endothelial and antigen-presenting cell activation, and facilitates the interaction of these cells with T cells and platelets. We demonstrate here that administration of a CD154-specific monoclonal antibody (hu5C8)...

  • Immunosuppression of organ allograft rejection by ultraviolet light. Du Toit, Don F.; Mouton, Yolande M. // South African Journal of Science;Feb97, Vol. 93 Issue 2, p56 

    Looks at research on the immunosuppressive properties and potential of ultraviolet light. Potential application of ultraviolet in prevention organ transplant rejection.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics